199 related articles for article (PubMed ID: 35671249)
1. Structural Feature Analyzation Strategies toward Discovery of Orally Bioavailable PROTACs of Bruton's Tyrosine Kinase for the Treatment of Lymphoma.
Zhang J; Che J; Luo X; Wu M; Kan W; Jin Y; Wang H; Pang A; Li C; Huang W; Zeng S; Zhuang W; Wu Y; Xu Y; Zhou Y; Li J; Dong X
J Med Chem; 2022 Jul; 65(13):9096-9125. PubMed ID: 35671249
[TBL] [Abstract][Full Text] [Related]
2. Discovery of Novel Bruton's Tyrosine Kinase PROTACs with Enhanced Selectivity and Cellular Efficacy.
Li YQ; Lannigan WG; Davoodi S; Daryaee F; Corrionero A; Alfonso P; Rodriguez-Santamaria JA; Wang N; Haley JD; Tonge PJ
J Med Chem; 2023 Jun; 66(11):7454-7474. PubMed ID: 37195170
[TBL] [Abstract][Full Text] [Related]
3. Discovery of novel BTK PROTACs with improved metabolic stability via linker rigidification strategy.
Chen S; Chen Z; Lu L; Zhao Y; Zhou R; Xie Q; Shu Y; Lin J; Yu X; Wang Y
Eur J Med Chem; 2023 Jul; 255():115403. PubMed ID: 37119666
[TBL] [Abstract][Full Text] [Related]
4. Discovery of novel BTK PROTACs for B-Cell lymphomas.
Zhao Y; Shu Y; Lin J; Chen Z; Xie Q; Bao Y; Lu L; Sun N; Wang Y
Eur J Med Chem; 2021 Dec; 225():113820. PubMed ID: 34509879
[TBL] [Abstract][Full Text] [Related]
5. Strategies for overcoming resistance to Bruton's tyrosine kinase inhibitor zanubrutinib.
Dostálová H; Kryštof V
Hematol Oncol; 2024 Jul; 42(4):e3294. PubMed ID: 38847437
[TBL] [Abstract][Full Text] [Related]
6. Discovery of Novel Potent and Fast BTK PROTACs for the Treatment of Osteoclasts-Related Inflammatory Diseases.
Huang J; Ma Z; Peng X; Yang Z; Wu Y; Zhong G; Ouyang T; Chen Z; Liu Y; Wang Q; Chen J; Chen T; Zeng Z
J Med Chem; 2024 Feb; 67(4):2438-2465. PubMed ID: 38321747
[TBL] [Abstract][Full Text] [Related]
7. Targeting the C481S Ibrutinib-Resistance Mutation in Bruton's Tyrosine Kinase Using PROTAC-Mediated Degradation.
Buhimschi AD; Armstrong HA; Toure M; Jaime-Figueroa S; Chen TL; Lehman AM; Woyach JA; Johnson AJ; Byrd JC; Crews CM
Biochemistry; 2018 Jul; 57(26):3564-3575. PubMed ID: 29851337
[TBL] [Abstract][Full Text] [Related]
8. Discovery of 5-Phenoxy-2-aminopyridine Derivatives as Potent and Selective Irreversible Inhibitors of Bruton's Tyrosine Kinase.
Lee E; Cho H; Lee DK; Ha J; Choi BJ; Jeong JH; Ryu JH; Kang JS; Jeon R
Int J Mol Sci; 2020 Oct; 21(21):. PubMed ID: 33126415
[TBL] [Abstract][Full Text] [Related]
9. Discovery of potent and selective reversible Bruton's tyrosine kinase inhibitors.
Qiu H; Ali Z; Bender A; Caldwell R; Chen YY; Fang Z; Gardberg A; Glaser N; Goettsche A; Goutopoulos A; Grenningloh R; Hanschke B; Head J; Johnson T; Jones C; Jones R; Kulkarni S; Maurer C; Morandi F; Neagu C; Poetzsch S; Potnick J; Schmidt R; Roe K; Viacava Follis A; Wing C; Zhu X; Sherer B
Bioorg Med Chem; 2021 Jun; 40():116163. PubMed ID: 33932711
[TBL] [Abstract][Full Text] [Related]
10. Medicinal Chemistry Strategies for the Development of Bruton's Tyrosine Kinase Inhibitors against Resistance.
Sun SL; Wu SH; Kang JB; Ma YY; Chen L; Cao P; Chang L; Ding N; Xue X; Li NG; Shi ZH
J Med Chem; 2022 Jun; 65(11):7415-7437. PubMed ID: 35594541
[TBL] [Abstract][Full Text] [Related]
11. Progress in the development of small molecular inhibitors of the Bruton's tyrosine kinase (BTK) as a promising cancer therapy.
Liu XJ; Xu-Liu ; Pang XJ; -Ying Yuan X; Yu GX; Li YR; Guan YF; Zhang YB; Song J; Zhang QR; Zhang SY
Bioorg Med Chem; 2021 Oct; 47():116358. PubMed ID: 34479103
[TBL] [Abstract][Full Text] [Related]
12. Design, synthesis and biological evaluation of Proteolysis Targeting Chimeras (PROTACs) as a BTK degraders with improved pharmacokinetic properties.
Jaime-Figueroa S; Buhimschi AD; Toure M; Hines J; Crews CM
Bioorg Med Chem Lett; 2020 Feb; 30(3):126877. PubMed ID: 31879210
[TBL] [Abstract][Full Text] [Related]
13. Review of the development of BTK inhibitors in overcoming the clinical limitations of ibrutinib.
Ran F; Liu Y; Wang C; Xu Z; Zhang Y; Liu Y; Zhao G; Ling Y
Eur J Med Chem; 2022 Feb; 229():114009. PubMed ID: 34839996
[TBL] [Abstract][Full Text] [Related]
14. Emerging small-molecule inhibitors of the Bruton's tyrosine kinase (BTK): Current development.
Liu J; Chen C; Wang D; Zhang J; Zhang T
Eur J Med Chem; 2021 May; 217():113329. PubMed ID: 33740548
[TBL] [Abstract][Full Text] [Related]
15. Next-generation Bruton's Tyrosine Kinase (BTK) Inhibitors Potentially Targeting BTK C481S Mutation- Recent Developments and Perspectives.
Das D; Wang J; Hong J
Curr Top Med Chem; 2022; 22(20):1674-1691. PubMed ID: 35927919
[TBL] [Abstract][Full Text] [Related]
16. Discovery and biological evaluation of N-(3-(7-((2-methoxy-4-(4-methylpiperazin-1-yl)phenyl)amino)-4-methyl-2-oxo-2H-pyrimido[4,5-d][1,3]oxazin-1(4H)-yl)phenyl)acrylamide as potent Bruton's tyrosine kinase inhibitors.
Lai MZ; Song PR; Dou D; Diao YY; Tong LJ; Zhang T; Xie H; Li HL; Ding J
Acta Pharmacol Sin; 2020 Mar; 41(3):415-422. PubMed ID: 31316181
[TBL] [Abstract][Full Text] [Related]
17. Delineating the role of cooperativity in the design of potent PROTACs for BTK.
Zorba A; Nguyen C; Xu Y; Starr J; Borzilleri K; Smith J; Zhu H; Farley KA; Ding W; Schiemer J; Feng X; Chang JS; Uccello DP; Young JA; Garcia-Irrizary CN; Czabaniuk L; Schuff B; Oliver R; Montgomery J; Hayward MM; Coe J; Chen J; Niosi M; Luthra S; Shah JC; El-Kattan A; Qiu X; West GM; Noe MC; Shanmugasundaram V; Gilbert AM; Brown MF; Calabrese MF
Proc Natl Acad Sci U S A; 2018 Jul; 115(31):E7285-E7292. PubMed ID: 30012605
[TBL] [Abstract][Full Text] [Related]
18. Role of Bruton's tyrosine kinase in B cells and malignancies.
Pal Singh S; Dammeijer F; Hendriks RW
Mol Cancer; 2018 Feb; 17(1):57. PubMed ID: 29455639
[TBL] [Abstract][Full Text] [Related]
19. Discovery of a BTK/MNK dual inhibitor for lymphoma and leukemia.
Wu H; Hu C; Wang A; Weisberg EL; Chen Y; Yun CH; Wang W; Liu Y; Liu X; Tian B; Wang J; Zhao Z; Liang Y; Li B; Wang L; Wang B; Chen C; Buhrlage SJ; Qi Z; Zou F; Nonami A; Li Y; Fernandes SM; Adamia S; Stone RM; Galinsky IA; Wang X; Yang G; Griffin JD; Brown JR; Eck MJ; Liu J; Gray NS; Liu Q
Leukemia; 2016 Jan; 30(1):173-81. PubMed ID: 26165234
[TBL] [Abstract][Full Text] [Related]
20. Discovery of novel dual Bruton's tyrosine kinase (BTK) and Janus kinase 3 (JAK3) inhibitors as a promising strategy for rheumatoid arthritis.
Liang T; Cen L; Wang J; Cheng M; Guo W; Wang W; Yu C; Zhang H; Wang Y; Hao Z; Jin J; Wu Y; Jiang T; Zhu Q; Xu Y
Bioorg Med Chem; 2023 Dec; 96():117354. PubMed ID: 37944414
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
